An Australian, phase II , multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide, and intravenous rituximab (poFCivR) tolerance in previously untreated elderly (=65years old) patients with chronic lymphocytic leukaemia. (CLL)

Trial Profile

An Australian, phase II , multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide, and intravenous rituximab (poFCivR) tolerance in previously untreated elderly (=65years old) patients with chronic lymphocytic leukaemia. (CLL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms OFOCIR
  • Most Recent Events

    • 04 Dec 2010 Interim results presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology
    • 01 Aug 2010 65 of the planned 120 patients were recruited by 1 August 2010
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top